The next generation of PDE4 inhibitors

Current Opinion in Chemical Biology

Volumn 5, Issue 4, 2001, Pages 432-438

  Huang, Zheng ^a   Ducharme, Yves ^a   Macdonald, Dwight ^a   Robichaud, Annette ^a  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [6,7 DIETHOXY 2,3 BIS(HYDROXYMETHYL) 1 NAPHTHYL] 2 PYRIDYL] 4 (3 PYRIDYL) 1(2H) PHTHALAZINONE; 4 (3 CHLOROPHENYL) 1,7 DIETHYLPYRIDO[2,3 D]PYRIMIDIN 2(1H) ONE; 7 METHOXYBENZOFURAN 4 CARBOXAMIDE DERIVATIVE; BAY 198004; CILOMILAST; CL 1044; L 791943; L 826141; NITRAQUAZONE DERIVATIVE; PHOSPHODIESTERASE IV INHIBITOR; PHTHALAZINE DERIVATIVE; ROFLUMILAST; UNCLASSIFIED DRUG;

ASTHMA; CATALYSIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CROHN DISEASE; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; DRUG STRUCTURE; ENZYME BINDING; IC 50; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; VOMITING;

EID: 0035416118     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(00)00224-6     Document Type: Review

References (94)

1. Genomic organization of the human phosphodiesterase PDE11A gene evolutionary relatedness with other PDEs containing GAF domains
2. Regulation of cAMP and cGMP signaling: New phosphodiesterases and new functions
3. The molecular biology of cyclic nucleotide phosphodiesterases
4. Phosphodiesterase isozymes: Molecular targets for novel antiasthma agents
5. Immunosuppressive and anti inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors
6. New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease
7. Acute anti-inflammatory effect of the novel phosphodiesterase 4 inhibitor roflumilast on allergen challenge in asthmatics after a single dose
8. Safety and efficacy of the new PDE 4 inhibitor roflumilast administered to patients with exercise-induced asthma over 4 weeks
9. Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: From concept to clinic
10. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis
11. Clinical effects of neurotropic selective cAMP phosphodiesterase inhibitor rolipram in depressed patients: Global evaluation of the preliminary reports
12. Emesis induced by inhibitors of type 4 cyclic nucleotide phosphodiesterase (PDE IV) in the ferret
13. Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD)
14. The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: Intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions
15. Tailoring cAMP-signalling responses through isoform multiplicity
16. PDE4 inhibitors: Sustained patenting activity as leading drugs near the market
17. Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, as promising agents for the treatment of asthma and other pathologies
18. Phosphodiesterase type 4 inhibitors: Potential in the treatment of multiple sclerosis?
19. Phosphodiesterase 4 inhibitors and the treatment of asthma: Where are we now and where do we go from here?
20. Phosphodiesterases 4D and 7A splice variants in the response of HUVEC cells to TNF-alpha(1)
21. Histamine up-regulates phosphodiesterase 4 activity and reduces prostaglandin E2-inhibitory effects in human neutrophils
22. Differential changes in the expression of cyclic nucleotide phosphodiesterase isoforms in rat brains by chronic treatment with electroconvulsive shock
23. Noradrenergic lesions differentially alter the expression of two subtypes of low Km cAMP-sensitive phosphodiesterase type 4 (PDE4A and PDE4B) in rat brain
24. Effects of repeated antidepressant treatment of type 4A phosphodiesterase (PDE4A) in rat brain
25. Induction of specific phosphodiesterase isoforms by constitutive activation of the cAMP pathway in autonomous thyroid adenomas
26. Short term feedback regulation of cAMP in FRTL-5 thyroid cells. Role of PDE4D3 phosphodiesterase activation
27. Expression of phosphodiesterase 4D (PDE4D) is regulated by both the cyclic AMP-dependent protein kinase and mitogen-activated protein kinase signaling pathways. A potential mechanism allowing for the coordinated regulation of PDE4D activity and expression in cells
28. Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation
29. Sub-family selective actions in the ability of erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterases
30. ERK2 mitogen-activated protein kinase binding, phosphorylation, and regulation of the PDE4D cAMP-specific phosphodiesterases. The involvement of COOH-terminal docking sites and NH2-terminal UCR regions
31. UCR1 and UCR2 domains unique to the cAMP-specific phosphodiesterase family form a discrete module via electrostatic interactions
32. Activation of the cAMP-specific phosphodiesterase PDE4D3 by phosphorylation. Identification and function of an inhibitory domain
33. The cAMP-specific phosphodiesterase PDE4D3 is regulated by phosphatidic acid binding, consequences for cAMP signaling pathway and characterization of a phosphatidic acid binding site
34. Expression of different phosphodiesterase genes in human cavernous smooth muscle
35. Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D
36. Recombinant expression of a type 4, cAMP-specific phosphodiesterase: Characterization and structure-function studies of deletion mutants
37. Zinc dependent activation of cAMP-specific phosphodiesterase (PDE4A)
38. Atomic structure of PDE4: Insights into phosphodiesterase mechanism and specificity
39. Conformational difference between PDE4 apoenzyme and holoenzyme
40. Analysis of a mutation in phosphodiesterase type 4 that alters both inhibitor activity and nucleotide selectivity
41. Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3
42. Comparison of recombinant human PDE4 isoforms: Interaction with substrate and human PDE4 isoforms: Interaction with substrate and inhibitors
43. Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases
44. Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H]rolipram binding
45. Pharmacokinetically governed design of animal toxicity studies of a new antidepressant drug
46. Emetic, central nervous system, and pulmonary activities of rolipram in the dog
47. Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms
48. Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect
49. Hunting the emesis and efficacy targets of PDE4 inhibitors: Identification of the photoaffinity probe 8-(3-azidophenyl)-6-[(4-iodo-1H-1-imidazolyl)methyl]quinoline (APIIMQ)
50. PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway
51. Selective potentiating effect of RS14203 on a serotoninergic pathway in anesthetized rats
52. Inhibition of adenylate cyclase in the locus coeruleus mediates the hypnotic response to an alpha 2 agonist in the rat
53. SmithKline Beecham reports earnings per share increase of 33 per cent for third quarter 2000, 24 per cent excluding currency
54. Molecular and cellular profile of the structurally novel phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004
55. Efficacy of the selective phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004, in a rat model of neutrophilic lung inflammation
56. The evaluation of a selective phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004, in guinea-pig antigen challenge and ferret emesis models
57. The effect of an oral phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004, in primate asthma models
58. Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: Discovery of potent, selective phosphodiesterase type 4 inhibitors
59. 7-Methoxybenzofuran-4-carboxamides as PDE 4 inhibitors: A potential treatment for asthma
60. Phenyl substituted analogs of CDP-840 as phosphodiesterase-4 inhibitors with improved potency, oral activity and metabolic stability
61. Substituted 4-(2,2-diphenylethyl)pyridine-N-oxides as phosphodiesterase-4 inhibitors: SAR study directed toward the improvement of pharmacokinetic parameters
62. The effects of phosphodiesterase type 4 inhibitors on tumour necrosis factor-alpha and leukotriene B4 in a novel human whole blood assay
63. Synthesis and biological evaluation of 2,5-dihydropyrazol
64. Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: Synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives
65. Effect of a novel anti-inflammatory compound, YM976, on antigen-induced eosinophil infiltration into the lungs in rats, mice, and ferrets
66. A novel phosphodiesterase type 4 inhibitor, YM976 (4-(3-chlorophenyl)-1,7-diethylpyrido[2,3-d]pyrimidin-2(1H)-one), with little emetogenic activity
67. The synthesis and biological evaluation of a novel series of phthalazine PDE4 inhibitors I
68. Phthalazine PDE4 inhibitors. Part 2: The synthesis and biological evaluation of 6-methoxy-1,4-disubstituted derivatives
69. Palladium-catalyzed cross-coupling reactions for the synthesis of 6, 8-disubstituted 1,7-naphthyridines: A novel class of potent and selective phosphodiesterase type 4D inhibitors
70. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B
71. Chronic obstructive pulmonary disease: Emerging therapies
72. The potential of PDE4 inhibitors in asthma or COPD
73. PDE4 inhibitors and chronic obstructive pulmonary disease
74. Phosphodiesterase 4 and tolerance to beta 2-adrenoceptor agonists in asthma
75. Desensitization of beta2-adrenoceptor and hypersensitization to phosphodiesterase inhibitors elicited by beta2-agonists in guinea pig eosinophils
76. Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: Synergism with prostanoids and salbutamol
77. Type 4 phosphodiesterase inhibitors attenuate respiratory syncytial virus-induced airway hyper-responsiveness and lung eosinophilia
78. Induction of apoptosis by an inhibitor of cAMP-specific PDE in malignant murine carcinoma cells overexpressing PDE activity in comparison to their nonmalignant counterparts
79. Cyclic 3′,5′-nucleotide phosphodiesterases: Potential targets for anticancer therapy
80. Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia
81. The cAMP signaling pathway as a therapeutic target in lymphoid malignancies
82. Infection of CD4+ memory T cells by HIV-1 requires expression of phosphodiesterase 4
83. Pivotal role of cyclic nucleoside phosphodiesterase 4 in tat-mediated CD4+ T cell hyperactivation and HIV type 1 replication
84. Inhibition of cytokine release by and cardiac effects of type 4 phosphodiesterase inhibition in early, profound endotoxaemia in vivo
85. Chronic type 4 phosphodiesterase inhibition protects glomerular filtration rate and renal and mesenteric blood flow in a zymosan-induced model of multiple organ dysfunction syndrome treated with norepinephrine
86. Inhibition of cyclic AMP phosphodiesterase (PDE4) reverses memory deficits associated with NMDA receptor antagonism
87. Effects of rolipram on scopolamine-induced impairment of working and reference memory in the radial-arm maze tests in rats
88. Identification of inhibitor binding sites of the cAMP-specific phosphodiesterase 4
89. Identification of substrate specificity determinants in human cAMP-specific phosphodiesterase 4A by single-point mutagenesis
90. mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module
91. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor Roflumilast in vitro
92. In vivo efficacy in airway disease models of Roflumilast, a novel orally active PDE4 inhibitor